DOLF

IDA Acceptability Study (Fiji)

Assess the overall acceptability of the 3-drug treatment in the community as compared to the 2-drug treatment

Countries: Fiji

IDA Acceptability Study (India)

Assess the overall acceptability of the 3-drug treatment in the community as compared to the 2-drug treatment

Countries: India

Triple Drug Therapy for LF

Comparison of safety profile and acceptability between triple drug therapy (IVM,DEC,ALB) and standard two-drug therapy (DEC, ALB), plus STH evaluation.

Triple Drug Therapy (India)

To determine the frequency, type and severity of adverse events following triple-drug therapy (IVM+DEC+ALB, IDA) compared to the standard two-drug treatment (DEC+ALB, DA) in infected and uninfected individuals in a community.

To compare the efficacy of IDA vs. DA administered in communities for clearance of Mf and filarial antigenemia (Ag) in cohort and effectiveness (prevalence) in community settings. To assess the presence and intensity of filarial infection on the frequency and severity of adverse events. To compare community acceptance of MDA with IDA vs. DA.

Countries: India

Randomized trial of Ivermectin/Albendazole vs. Ivermectin alone

Randomized clinical trail comparing treatment with Albendazole and Ivermectin to Ivermectin alone for Onchocerciasis.

Countries: Ghana
Diseases: Onchocerciasis

Randomized trial of albendazole alone for LF in Cote d'Ivoire

Randomized Clinical Trial of Albendazole vs Ivermectin+Albendazole for lymphatic filariasis treatment and elimination.

Countries: Cote d'Ivoire

Randomized trial of triple therapy (DEC/Alb/Iver) in Papua New Guinea

Randomized Clinical Trial comparing triple triple therapy of DEC/Alb/Iver vs. DEC/Alb alone

Countries: Papua New Guinea

Analysis of MDA frequency and Brugia in Indonesia

Comparison of 2X vs. 1X per year MDA on Brugia with MDA of DEC/Alb , plus STH evaluation

Countries: Indonesia

Analysis of MDA for LF in loa endemic countries

Community MDA with 2X Alb alone for W. bancrofti in areas co-endemic for L. loa, plus STH evaluation

Countries: Congo | Dem. Rep. of Congo

Pages